Cytomx analysts
WebMar 31, 2024 · CytomX Therapeutics, Inc. (NASDAQ:CTMX– Get Rating) – Stock analysts at HC Wainwright raised their Q1 2024 earnings per share estimates for CytomX Therapeutics in a report released on... WebFeb 5, 2024 · When CytomX Therapeutics last reported its balance sheet in September 2024, it had zero debt and cash worth US$236m. Looking at the last year, the company burnt through US$107m. That means it had...
Cytomx analysts
Did you know?
WebApr 9, 2024 · 8 Analysts CTMX Stock Overview CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. About the company Risk Analysis Negative shareholders equity Currently unprofitable and not forecast to become profitable over the next 3 years See All Risk Checks My Notes WebApr 14, 2024 · CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Rating of “Hold” from Analysts Globe Life (NYSE:GL) PT Lowered to $129.00 Morgan Stanley Lowers ICL Group (NYSE:ICL) Price Target to $7.50
WebAnalyst jobs 760,055 open jobs Coordinator jobs 540,291 open jobs Help Desk Technician jobs 5,545 open jobs Administrator jobs 476,673 open jobs ... WebCompany Type For Profit. Phone Number 6503510353. CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. …
WebMar 20, 2024 · CytomX Therapeutics Price Performance. Shares of NASDAQ:CTMX opened at $1.86 on Monday. The company has a market capitalization of $122.91 million, a price-to-earnings ratio of -1.25 and a beta of ... WebApr 6, 2024 · Find the latest CytomX Therapeutics, Inc. (CTMX) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears.
WebApr 13, 2024 · This is a summary of recent ratings and recommmendations for CytomX Therapeutics and Stoke Therapeutics, as provided by MarketBeat. CytomX Therapeutics currently has a consensus price target of $3.17, indicating a potential upside of 94.57%. Stoke Therapeutics has a consensus price target of $24.57, indicating a potential upside …
WebApr 14, 2024 · The company has a market cap of £24.70 billion, a P/E ratio of 3,198.81, a PEG ratio of 1.90 and a beta of 0.51. Experian has a 12-month low of GBX 2,242 ($27.76) and a 12-month high of GBX 3,160 ... reading mind in the eyes test auswertungWebNasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given … reading mind in the eyes test pdfWebCTMX Stock 12 Months Forecast. Based on 4 Wall Street analysts offering 12 month price targets for CytomX Therapeutics in the last 3 months. The average price target is $2.48 … reading minds 5eWebCytomX Therapeutics, Inc. (CTMX) Analyst Ratings, Estimates & Forecasts - Yahoo Finance U.S. markets open in 3 hours 21 minutes S&P Futures +19.25(+0.48%) Dow … reading mind in the eye testWebBuild your future. DXC is where brilliant people embrace change and seize opportunities to advance their careers and amplify customer success. 240+. customers in the. Fortune … reading military ordersWebMar 31, 2024 · CytomX Therapeutics, Inc. (CTMX) Stock Price Today, Quote & News Seeking Alpha CTMX CytomX Therapeutics, Inc. Stock Price & Overview 3.73K … reading military gridWebGlassdoor gives you an inside look at what it's like to work at CytomX Therapeutics, including salaries, reviews, office photos, and more. This is the CytomX Therapeutics … how to subtract a constant value in excel